In conclusion, we investigated the impact of SBP treatment on depressive‐like behavior in rats with depression following AMI, potentially achieved through amelioration of neuroinflammation and microglial pyroptosis mediated, at least partially, by the NLRP3/Caspase‐1/GSDMD signaling pathway. Here, NLRP3 is linked to depressive symptom measurement.